Notizie AIOM – anno XVII – Pagina 59

9 Maggio 2019

CancerLinQ LLC Collaborating with the International Association for the Study of Lung Cancer

May 7, 2019 - CancerLinQ LLC and the International Association for the Study of Lung Cancer (IASLC) have announced a collaboration to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, ...
Leggi tutto

9 Maggio 2019

Working together for safe medicines in the EU

May 6, 2019 - EMA launches a social media campaign to highlight how the European medicines regulatory network keeps medicines available in Europe safe and effective. As of today, EMA will start sharing a series of info-cards on its Twitter and LinkedIn accounts. The visuals ...
Leggi tutto

7 Maggio 2019

Re-analysis of data on use of breast cancer medicine Lapatinib following treatment with trastuzumab

April 30, 2019 - EMA is updating the prescribing information for lapatinib following detection of errors in results of a study involving postmenopausal women who had ‘HR+/HER2+’ breast cancer and whose disease had worsened despite previous treatment with trastuzumab. ...
Leggi tutto

6 Maggio 2019

The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers

This study evaluated the humanistic burden on caregivers of patients with advanced non-small cell lung cancer (aNSCLC) as the disease progresses. Data were drawn from a cross-sectional study of patients with aNSCLC and their caregivers conducted in France, Germany, and Italy ...
Leggi tutto

6 Maggio 2019

Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection

Organ-transplanted patients have a significantly higher risk of developing solid tumors (1). These patients are systematically excluded from clinical trials, so their available therapeutic options are very limited. With the incorporation of immunotherapy to cancer treatment ...
Leggi tutto

6 Maggio 2019

FDA Approves Adjuvant T-DM1 in HER2+ Early Breast Cancer

May 3, 2019 - The FDA has approved ado-trastuzumab emtansine (T-DM1) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy. The approval is based on findings ...
Leggi tutto

6 Maggio 2019

EMA annual report 2018 published

May 3, 2019 - The annual report published today provides an overview of the Agency’s activities to protect and promote the health of people and animals in the EU and highlights EMA’s most significant achievements in 2018. As in previous editions, an entire chapter ...
Leggi tutto

3 Maggio 2019

FDA Approval Sought for Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

April 29, 2019 - A supplemental new drug application (sNDA) has been submitted to the FDA for the approval of apalutamide for use as a treatment of patients with metastatic castration-sensitive prostate cancer, according to Janssen, the manufacturer of the next-generation ...
Leggi tutto

3 Maggio 2019

Statement from FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., and Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health on FDA’s new efforts to protect women’s health and help to ensure the safety of breast implants

May 2, 2019 - There has been a growing discussion in recent months around the safety of certain breast implants, with regulatory agencies around the world weighing the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). It’s an issue that has ...
Leggi tutto

3 Maggio 2019

FDA Approves Ivosidenib for Frontline IDH1+ AML

May 2, 2019 - The FDA has approved a supplemental new drug application (sNDA) for ivosidenib as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia (AML), as detected by an FDA-approved test, who are ≥75 years old or ...
Leggi tutto

LAVORIAMO CON

News

FUMO: “IN 4 ANNI RADDOPPIATO L’USO DI SIGARETTE ELETTRONICHE E TABACCO RISCALDATO. GIÀ 40.000 CITTADINI HANNO FIRMATO PER AUMENTARE DI 5 EURO IL COSTO DEI PRODOTTI DA FUMO”

TUMORE DELLA PROSTATA: AIFA APPROVA DAROLUTAMIDE PIÙ TERAPIA DI DEPRIVAZIONE ADROGENICA. MIGLIORA IL CONTROLLO DELLA MALATTIA E LA QUALITÀ DI VITA

LA PREVENZIONE DEL MELANOMA: AL VIA UNA CAMPAGNA NEI COOP.FI

TUMORI: “AIFA APPROVA LA FORMULAZIONE SOTTOCUTANEA E TRE NUOVE INDICAZIONI TERAPEUTICHE DI NIVOLUMAB”

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

Notizie AIOM – anno XVII

CancerLinQ LLC Collaborating with the International Association for the Study of Lung Cancer

Working together for safe medicines in the EU

Re-analysis of data on use of breast cancer medicine Lapatinib following treatment with trastuzumab

The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers

Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection

FDA Approves Adjuvant T-DM1 in HER2+ Early Breast Cancer

EMA annual report 2018 published

FDA Approval Sought for Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

Statement from FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., and Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health on FDA’s new efforts to protect women’s health and help to ensure the safety of breast implants

FDA Approves Ivosidenib for Frontline IDH1+ AML